Asthma  >>  Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
QVM149, NCT03108027 / 2017-000644-17: Assess Bronchodilator Effect Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma

Completed
2
38
Europe
Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose), Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose), Treatment C: Placebo (morning dose) and placebo (evening dose)
Novartis Pharmaceuticals
Asthma
02/18
02/18
NCT03063086 / 2016-005164-34: Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Completed
2
116
Europe, RoW
QVM149 150/50/80 μg o.d., QVM149 150/50/160 μg o.d., salmeterol/fluticasone FDC 50/500 μg b.i.d.
Novartis Pharmaceuticals
Asthma
08/18
08/18

Download Options